buche

BuChE-IN-TM-10 (TM-10) is a potent inhibitor of butyrylcholinesterase (BuChE) with an IC50 of 8.9 nM. It effectively inhibits and disaggregates self-induced Aβ aggregation, exhibits significant antioxidant activity, and demonstrates substantial penetration through the blood-brain barrier (BBB), holding promise as a potential treatment for Alzheimer's disease.

Butyrylcholinesterase (BCHE), Horse Serum (also known as BCHE, BuChE, PCHE, pseudocholinesterase, plasmacholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl) is a biomaterial or organic compound utilized in life science research.

BuChE-IN-15, a chemical compound, exhibits potent inhibitory activity with IC50 values of 81 nM and 400 nM, respectively. It also demonstrates good blood-brain barrier permeability and neuroprotective properties, making it suitable for research in Alzheimer's disease.

AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. It exhibits strong DPPH radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies demonstrate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical parameters compared to controls, and no abnormalities in liver and kidney tissues. This compound shows potential for Alzheimer's disease research.

BuChE-IN-16 (Compound 6a) is an orally active, blood-brain barrier-permeable, and selective BuChE inhibitor with an IC50 of 0.33 μM. It exhibits anti-inflammatory and neuroprotective effects, improves cognitive function in Alzheimer's disease (AD) zebrafish models, and alleviates scopolamine-induced memory impairment in mice. BuChE-IN-16 is applicable for Alzheimer's disease research.

BuChE-IN-20 is a selective hBuChE inhibitor (IC50= 0.13 μM) with the ability to cross the blood-brain barrier (BBB). This compound, a derivative of L-Tryptophan, exhibits neuroprotective effects by inhibiting nitric oxide (NO) production and reducing reactive oxygen species (ROS) levels. It effectively suppresses the self-aggregation of amyloid-beta (Aβ) peptides and is applicable in Alzheimer's disease research.

BuChE-IN-21 (compound SXF3) is a potent and selective inhibitor of BuChE, demonstrating inhibitory effects on eqBuChE and hBuChE with IC50 values of 0.05 and 0.04 μM, respectively. Additionally, BuChE-IN-21 exhibits significant anti-inflammatory activity.

BuChE-IN-10 (compound 7p) is a BuChE inhibitor with eqBuChEIC50 of 4.68 nM and huBuChEIC50 of 9.12 nM. It demonstrates anti-neuroinflammatory properties and exhibits high blood-brain barrier (BBB) permeability.

AChE/BuChE-IN-5 (compound 5a) is a dual-target inhibitor with potent nanomolar inhibitory activity against acetylcholinesterase (AChE) (IC50=46.9 nM) and butyrylcholinesterase (BuChE) (IC50=3.5 nM). This compound is useful for Alzheimer's disease research.

BuChE-IN-11 (Compound 3b-1) is a selective inhibitor of BuChE with an IC50 of 0.44 μM for hBuChE. The compound demonstrates high brain-blood barrier permeability and possesses free radical scavenging capabilities, indicating significant antioxidant activity. BuChE-IN-11 interacts with the choline binding site, the acyl binding site, and the peripheral anionic site, showing submicromolar inhibitory activity against BuChE and preventing the self-aggregation of β-amyloid protein (Aβ). This compound holds promise for research in the field of Alzheimer's disease.

AChE/BuChE-IN-2 (Compound 5f) is an orally active inhibitor of AChE and BuChE with IC50 values of 0.72 μM and 0.16 μM, respectively, and can cross the BBB. AChE/BuChE-IN-2 shows potent inhibition of self-induced β-amyloid (Aβ) aggregation with an IC50 of 62.52 μM and demonstrates non-competitive inhibition with AChE [1].

BuChE-IN-6 (compound 1b) is a highly effective and specific inhibitor of BuChE (butyrylcholinesterase), with IC50 values of 0.46 μM for eqBuChE and 0.51 μM for hBuChE. Additionally, it inhibits the self-aggregation of Aβ 42 [1].

BuChE-IN-5 (compound 25b) is a highly potent BuChE inhibitor with an IC50 value of 1.94 μM, effectively inhibiting Aβ and tau protein aggregation in Escherichia coli, and demonstrating significant free radical scavenging and antioxidant activity, making it a valuable tool for Alzheimer's disease research [1].

BuChE-IN-1 (Compound 23) is a potent, highly blood-brain barrier-permeable, low cytotoxicity inhibitor of butyrylcholinesterase (BuChE), with potential applications in Alzheimer's disease (AD) research.

BuChE-IN-3 (Compound C4) is a potent inhibitor of BuChE (IC50: 8.3 nM), as well as a mild antioxidant, non-toxic, lipophilic, and neuroprotective agent.

BuChE-IN-4 is a potent inhibitor of BuChE (IC50: 7.7 nM) and exhibits mild antioxidant capacity, non-toxicity, lipophilicity and neuroprotective effects.

BuChE-IN-2 is an excellent inhibitor of butylcholinesterase (BuChE) with IC50 values of 1.28 μM for BuChE and 0.67 μM for NO. It inhibits Aβ aggregation, ROS formation, and Cu2+ chelation, shows proper blood-brain barrier (BBB) penetration, and is suitable for Alzheimer's disease research.

AChE/BuChE-IN-3 is a potent inhibitor of AChE (IC50: 0.65 μM) and BuChE (IC50: 5.77 μM) that crosses the blood-brain barrier and inhibits the aggregation of Aβ1-42, suitable for Alzheimer's disease research.

AChE/BuChE-IN-1, a selective butyrylcholinesterase (BuChE) inhibitor derived from chrysin, exhibits a potent efficacy with an IC50 of 0.48 μM against BuChE and a lesser inhibitory effect on acetylcholinesterase (AChE) with an IC50 of 7.16 μM. It demonstrates significant hydroxyl radical (·OH) scavenging activity, achieving an IC50 of 0.1674 μM, and effectively inhibits reactive oxygen species (ROS) and Aβ 1-42 aggregation, including self-aggregation, copper (Cu 2+)-induced, and AChE-induced aggregation. Characterized by high blood-brain barrier (BBB) permeability, bioavailability, and low cellular toxicity, AChE/BuChE-IN-1 holds promising potential for Alzheimer's disease (AD) research.

BuChE-IN-7 is a selective inhibitor targeting human butyrylcholinesterase (hBuChE) and equine butyrylcholinesterase (eqBuChE), demonstrating IC50 values of 40 nM and 80 nM, respectively. Demonstrating the ability to penetrate the blood-brain barrier, BuChE-IN-7 enhances cognitive functions and specifically augments situational and phobic memory, exhibiting a preference for novelty.

AChE/BuChE-IN-4 is a multi-target AChE/BuChE inhibitor with oral activity and blood-brain barrier permeability, with IC50 values of 2.08 and 7.41 μM for AChE and BuChE, respectively.

AChE/BuChE/MAO-B-IN-2 (compound 4b) is a potent inhibitor of AChE, BuChE, and hu MAO-B, with respective IC50 values of 5.3 μM, 12.4 μM, and 1.9±0.08 μM, indicating good in vitro blood-brain barrier (BBB) permeability. It effectively reduces excessive AChE and BuChE levels associated with Alzheimer's disease (AD) and holds potential for anti-Alzheimer's research [1].

BuChE-IN-8 (compound 19c), a butyrylcholinesterase (BuChE) inhibitor, exhibits an IC50 value of 559 nM and concurrently inhibits human β-secretase (BACE1) and Aβ40 aggregation. It also demonstrates notable antiamnesic properties [1].

BuChE-IN-9 (compound 22a), an eqBuChE (equine serum-derived butyrylcholinesterase) inhibitor, exhibits potent activity with an IC50 of 173 nM. In addition to eqBuChE, it also inhibits human BACE1, Aβ aggregation, and mouse GABA transporters 1 and 4 (mGAT1 and mGAT4). Notably, BuChE-IN-9 demonstrates significant antiamnesic properties [1].